GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » ROA %

ENZ (Enzo Biochem) ROA % : -59.73% (As of Jul. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Enzo Biochem's annualized Net Income for the quarter that ended in Jul. 2024 was $-53.52 Mil. Enzo Biochem's average Total Assets over the quarter that ended in Jul. 2024 was $89.62 Mil. Therefore, Enzo Biochem's annualized ROA % for the quarter that ended in Jul. 2024 was -59.73%.

The historical rank and industry rank for Enzo Biochem's ROA % or its related term are showing as below:

ENZ' s ROA % Range Over the Past 10 Years
Min: -26.02   Med: -2.86   Max: 50.26
Current: -25.74

During the past 13 years, Enzo Biochem's highest ROA % was 50.26%. The lowest was -26.02%. And the median was -2.86%.

ENZ's ROA % is ranked worse than
66.52% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: -4.83 vs ENZ: -25.74

Enzo Biochem ROA % Historical Data

The historical data trend for Enzo Biochem's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem ROA % Chart

Enzo Biochem Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.02 6.96 -19.29 20.55 -25.12

Enzo Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 236.90 -23.19 -11.92 -12.55 -59.73

Competitive Comparison of Enzo Biochem's ROA %

For the Diagnostics & Research subindustry, Enzo Biochem's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's ROA % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's ROA % distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's ROA % falls into.



Enzo Biochem ROA % Calculation

Enzo Biochem's annualized ROA % for the fiscal year that ended in Jul. 2024 is calculated as:

ROA %=Net Income (A: Jul. 2024 )/( (Total Assets (A: Jul. 2023 )+Total Assets (A: Jul. 2024 ))/ count )
=-26.078/( (121.88+85.764)/ 2 )
=-26.078/103.822
=-25.12 %

Enzo Biochem's annualized ROA % for the quarter that ended in Jul. 2024 is calculated as:

ROA %=Net Income (Q: Jul. 2024 )/( (Total Assets (Q: Apr. 2024 )+Total Assets (Q: Jul. 2024 ))/ count )
=-53.524/( (93.469+85.764)/ 2 )
=-53.524/89.6165
=-59.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jul. 2024) net income data. ROA % is displayed in the 30-year financial page.


Enzo Biochem  (NYSE:ENZ) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jul. 2024 )
=Net Income/Total Assets
=-53.524/89.6165
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-53.524 / 30.104)*(30.104 / 89.6165)
=Net Margin %*Asset Turnover
=-177.8 %*0.3359
=-59.73 %

Note: The Net Income data used here is four times the quarterly (Jul. 2024) net income data. The Revenue data used here is four times the quarterly (Jul. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Enzo Biochem ROA % Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem Business Description

Traded in Other Exchanges
Address
21 Executive Boulevard, Farmingdale, NY, USA, 11735
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203